Veracyte Inc

Отворен

СекторЗдравеопазване

41.21 -3.04

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

40.98

Максимум

43.6

Ключови измерители

By Trading Economics

Приходи

-3.2M

25M

Продажби

11M

150M

P/E

Средно за сектора

33.774

57.002

EPS

0.37

Марж на печалбата

16.957

Служители

755

EBITDA

-11M

24M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+35.56% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-718M

3.7B

Предишно отваряне

44.25

Предишно затваряне

41.21

Настроения в новините

By Acuity

50%

50%

171 / 340 Класиране в Healthcare

Veracyte Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 19:51 ч. UTC

Veracyte Inc shares are lower today, breaking a trend of higher closes. No specific news was identified for this decline amid notable market volume.

12.08.2026 г., 20:01 ч. UTC

Veracyte Inc shares are lower today, following a broader market decline. The stock remains significantly below its 20-day moving average.

11.08.2026 г., 19:26 ч. UTC

News

Veracyte Inc reported second-quarter revenue of $150.32 million and raised its 2026 outlook to $590 million to $596 million, boosting shares higher.

10.08.2026 г., 19:36 ч. UTC

News

Veracyte Inc shares declined Monday, trading lower since Friday's close amid broader market volatility and rising oil prices affecting inflation expectations.

7.08.2026 г., 19:26 ч. UTC

Correlated Moves

Veracyte Inc shares are higher, supported by a rise in the ARK Genomic Revolution ETF and broader small-cap strength from the Russell 2000 Index.

6.08.2026 г., 19:26 ч. UTC

Veracyte Inc shares are higher today, despite earlier losses. No specific news was identified to explain the price movement during the session.

5.08.2026 г., 19:32 ч. UTC

Veracyte Inc's shares are lower, reflecting broader market sentiment amid recent crude oil price declines. Trading volume is unusually high today.

4.08.2026 г., 19:36 ч. UTC

News
Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3.08.2026 г., 20:06 ч. UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1.08.2026 г., 00:01 ч. UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31.07.2026 г., 20:02 ч. UTC

News
Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30.07.2026 г., 23:21 ч. UTC

News
Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29.07.2026 г., 19:47 ч. UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28.07.2026 г., 15:22 ч. UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27.07.2026 г., 20:14 ч. UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24.07.2026 г., 22:16 ч. UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22.07.2026 г., 20:13 ч. UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21.07.2026 г., 17:16 ч. UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20.07.2026 г., 20:01 ч. UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Сравнение с други в отрасъла

Ценова промяна

Veracyte Inc Прогноза

Ценова цел

By TipRanks

35.56% нагоре

12-месечна прогноза

Среден 57.75 USD  35.56%

Висок 70 USD

Нисък 44 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Veracyte Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

8

Купи

1

Задържане

1

Продай

Настроение

By Acuity

171 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat